BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) posted its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, Zacks reports. BioNexus Gene Lab had a negative return on equity of 37.43% and a negative net margin of 54.70%.The business had revenue of $0.02 million for the quarter.
BioNexus Gene Lab Price Performance
BGLC opened at $2.30 on Friday. The company has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $2.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.69 and a current ratio of 6.53. BioNexus Gene Lab has a 52 week low of $1.92 and a 52 week high of $15.60. The firm has a market capitalization of $5.56 million, a PE ratio of -1.55 and a beta of 4.06.
Institutional Investors Weigh In On BioNexus Gene Lab
An institutional investor recently raised its stake in BioNexus Gene Lab stock. DRW Securities LLC increased its position in shares of BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 226.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,830 shares of the company’s stock after acquiring an additional 33,179 shares during the quarter. DRW Securities LLC owned about 2.02% of BioNexus Gene Lab worth $189,000 as of its most recent SEC filing. 18.85% of the stock is owned by institutional investors and hedge funds.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Stories
- Five stocks we like better than BioNexus Gene Lab
- The Market Has Ollie’s Bargain Outlet Completely Wrong
- Macy’s Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
